![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
National Cancer Centre, Singapore |
---|---|
Information provided by: | National Cancer Centre, Singapore |
ClinicalTrials.gov Identifier: | NCT00702481 |
The purpose of this study is to define the response and toxicities with the addition of Nimotuzumab to chemoradiation for head and neck cancer
Condition | Intervention | Phase |
---|---|---|
Head and Neck Cancer |
Drug: Nimotuzumab Drug: Cisplatin Radiation: Radiotherapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) |
Estimated Enrollment: | 37 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | April 2011 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Nimotuzumab/CDDP/RT: Experimental
Open label treatment arm
|
Drug: Nimotuzumab
Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
Drug: Cisplatin
Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
Radiation: Radiotherapy
Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
|
Epidermal Growth Factor Receptor (EGFR) is overexpressed in Head and Neck Squamous Cell Carcinoma (HNSCC). EGFR pathway activation is associated with tumor growth, decreased apoptosis, and increased angiogenesis. These present a putative target for the use of EGFR inhibitors either in the form of small molecule inhibitors or monoclonal antibodies. Several studies have been advanced that suggest application of these targeted therapies show promising responses with little additional toxicity. The addition of EGFR monoclonal antibodies to radiation results in better response rates and locoregional control compared to radiation alone. Addition of EGFR monoclonal antibodies compared to chemotherapy alone also improves the response rates in patients with advanced HNSCC.
Nimotuzumab is a humanized chimeric monoclonal antibody specific to the extracellular domain of EGFR. Several studies are ongoing and demonstrate promising efficacy of Nimotuzumab as monotherapy and in combination with radiation in HNSCC, and in combination with chemoradiation in Nasopharyngeal Carcinoma. This phase II clinical trial examines the feasibility of EGFR inhibition using Nimotuzumab in combination with concurrent chemoradiotherapy in locally advanced unresectable HNSCC. Successful and safe incorporation of an EGFR monoclonal antibody into the concurrent chemoradiation paradigm used to treat locally advanced HNSCC will represent an important advance in the optimisation of treatment for this group of patients.
Ages Eligible for Study: | 21 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients must have normal organ and marrow function as defined below:
AST(SGOT)/ALT(SGPT) < 2.5X normal
Exclusion Criteria:
Contact: Wan-Teck Lim, MD | +65-64368200 | dmolwt@nccs.com.sg |
Contact: Eng-Huat Tan, MD | +65-64368171 | dmoteh@nccs.com.sg |
Singapore | |
National Cancer Center Singapore | Recruiting |
Singapore, Singapore, 169610 | |
Principal Investigator: Wan-Teck Lim, MD |
Principal Investigator: | Wan-Teck Lim, MD | National Cancer Center Singapore |
Responsible Party: | National Cancer Center Singapore ( Dr Wan-Teck Darren Lim ) |
Study ID Numbers: | IB/NCCS-01 |
Study First Received: | June 19, 2008 |
Last Updated: | February 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00702481 History of Changes |
Health Authority: | Singapore: Health Sciences Authority |
Head and Neck Squamous Cell Cancer Chemoradiation EGFR monoclonal antibody |
Carcinoma, Squamous Cell of Head and Neck Squamous Cell Carcinoma Carcinoma Antibodies, Monoclonal Antibodies Cisplatin Radiation-Sensitizing Agents |
Head and Neck Neoplasms Epidermoid Carcinoma Neoplasms, Squamous Cell Carcinoma, Squamous Cell Neoplasms, Glandular and Epithelial Immunoglobulins |
Neoplasms by Histologic Type Antineoplastic Agents Physiological Effects of Drugs Pharmacologic Actions Carcinoma Neoplasms Neoplasms by Site |
Cisplatin Radiation-Sensitizing Agents Head and Neck Neoplasms Therapeutic Uses Neoplasms, Squamous Cell Carcinoma, Squamous Cell Neoplasms, Glandular and Epithelial |